Connection
Myron Levin to Herpes Zoster
This is a "connection" page, showing publications Myron Levin has written about Herpes Zoster.
|
|
Connection Strength |
|
 |
|
 |
|
18.373 |
|
|
|
-
Weinberg A, Scott Schmid D, Leung J, Johnson MJ, Miao C, Levin MJ. Predictors of 5-Year Persistence of Antibody Responses to Zoster Vaccines. J Infect Dis. 2023 11 11; 228(10):1367-1374.
Score: 0.665
-
Levin MJ, Weinberg A. Immune Responses to Varicella-Zoster Virus Vaccines. Curr Top Microbiol Immunol. 2023; 438:223-246.
Score: 0.627
-
Johnson RW, Levin MJ. Herpes Zoster and Its Prevention by Vaccination. Interdiscip Top Gerontol Geriatr. 2020; 43:131-145.
Score: 0.519
-
Levin MJ, Weinberg A. Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine. Clin Infect Dis. 2020 03 17; 70(7):1509-1515.
Score: 0.516
-
Weinberg A, Pang L, Johnson MJ, Caldas Y, Cho A, Tovar-Salazar A, Canniff J, Schmader KE, Popmihajlov Z, Levin MJ. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity. J Virol. 2019 08 01; 93(15).
Score: 0.493
-
Heineman TC, Cunningham A, Levin M. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr Opin Immunol. 2019 08; 59:42-48.
Score: 0.485
-
Levin MJ, Weinberg A. Immune responses to zoster vaccines. Hum Vaccin Immunother. 2019; 15(4):772-777.
Score: 0.477
-
Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ. Costs of herpes zoster complications in older adults: A cohort study of US claims database. Vaccine. 2019 02 21; 37(9):1235-1244.
Score: 0.477
-
Cunningham AL, Levin MJ. Herpes Zoster Vaccines. J Infect Dis. 2018 09 22; 218(suppl_2):S127-S133.
Score: 0.466
-
Weinberg A, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Levin MJ. Comparative Immune Responses to Licensed Herpes Zoster Vaccines. J Infect Dis. 2018 09 22; 218(suppl_2):S81-S87.
Score: 0.466
-
Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. Vaccine. 2018 10 29; 36(45):6810-6818.
Score: 0.466
-
Levin MJ, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Weinberg A. Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest. 2018 10 01; 128(10):4429-4440.
Score: 0.460
-
Erlandson KM, Streifel A, Novin AR, Hawkins KL, Foster C, Langness J, Bessesen M, Falutz J, Moanna A, Looney D, Johns ST, Nguyen JB, Oxman MN, Levin MJ. Low Rates of Vaccination for Herpes Zoster in Older People Living With HIV. AIDS Res Hum Retroviruses. 2018 07; 34(7):603-606.
Score: 0.455
-
Levin MJ, Cai GY, Lee KS, Rouphael NG, Mehta AK, Canniff J, Mulligan MJ, Weinberg A. Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine. J Infect Dis. 2018 03 13; 217(7):1055-1059.
Score: 0.449
-
Levin MJ, Bresnitz E, Popmihajlov Z, Weinberg A, Liaw KL, Willis E, Curtis JR. Studies with herpes zoster vaccines in immune compromised patients. Expert Rev Vaccines. 2017 12; 16(12):1217-1230.
Score: 0.439
-
Levin MJ, Weinberg A, Schmid DS. Herpes Simplex Virus and Varicella-Zoster Virus. Microbiol Spectr. 2016 06; 4(3).
Score: 0.397
-
Beals CR, Railkar RA, Schaeffer AK, Levin Y, Kochba E, Meyer BK, Evans RK, Sheldon EA, Lasseter K, Lang N, Weinberg A, Canniff J, Levin MJ. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. Lancet Infect Dis. 2016 08; 16(8):915-22.
Score: 0.393
-
Levin MJ. Varicella-zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections. J Clin Virol. 2014 Dec; 61(4):487-95.
Score: 0.354
-
Chen SY, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S, Levin MJ. Incidence of herpes zoster in patients with altered immune function. Infection. 2014 Apr; 42(2):325-34.
Score: 0.333
-
Levin MJ, Schmader KE, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis. 2013 Nov 01; 208(9):1386-90.
Score: 0.326
-
Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012 Aug; 24(4):494-500.
Score: 0.304
-
Tyring SK, Stek JE, Smith JG, Xu J, Pagnoni M, Chan IS, Silber JL, Parrino J, Levin MJ. Varicella-zoster virus-specific enzyme-linked immunospot assay responses and zoster-associated pain in herpes zoster subjects. Clin Vaccine Immunol. 2012 Sep; 19(9):1411-5.
Score: 0.303
-
Weinberg A, Huang S, Song LY, Fenton T, Williams P, Patterson J, Tovar-Salazar A, Levin MJ. Immune correlates of herpes zoster in HIV-infected children and youth. J Virol. 2012 Mar; 86(5):2878-81.
Score: 0.291
-
Frazer IH, Levin MJ. Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Curr Opin Virol. 2011 Oct; 1(4):268-79.
Score: 0.287
-
Levin MJ, Gershon AA, Dworkin RH, Brisson M, Stanberry L. Prevention strategies for herpes zoster and post-herpetic neuralgia. J Clin Virol. 2010 May; 48 Suppl 1:S14-9.
Score: 0.260
-
Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol. 2010; 342:341-57.
Score: 0.255
-
Levin MJ, Anderson JP, Seage GR, Williams PL. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr. 2009 Feb 01; 50(2):182-91.
Score: 0.239
-
Levin MJ, DeBiasi RL, Bostik V, Schmid DS. Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine. J Infect Dis. 2008 Nov 15; 198(10):1444-7.
Score: 0.235
-
Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008 Mar 15; 197(6):825-35.
Score: 0.225
-
Brisson M, Pellissier JM, Levin MJ. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis. 2007 Dec 01; 45(11):1527-9.
Score: 0.220
-
Johnson R, McElhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis. 2007 Nov; 11 Suppl 2:S43-8.
Score: 0.219
-
Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007 Nov 28; 25(49):8326-37.
Score: 0.218
-
Levin MJ, Schmader K. Prevention strategies: herpes zoster, post-herpetic neuralgia and immunogenicity. Herpes. 2007 Sep; 14 Suppl 2:45-7.
Score: 0.217
-
Weinberg A, Wiznia AA, LaFleur BJ, Shah S, Levin MJ. Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2004 Jul 15; 190(2):267-70.
Score: 0.173
-
Laing KJ, Ford ES, Johnson MJ, Levin MJ, Koelle DM, Weinberg A. Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity. J Clin Invest. 2023 12 01; 133(23).
Score: 0.167
-
Levin MJ, Dahl KM, Weinberg A, Giller R, Patel A, Krause PR. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis. 2003 Oct 01; 188(7):954-9.
Score: 0.165
-
Callegaro A, Burny W, Herv? C, Hyung Kim J, Levin MJ, Zahaf T, Cunningham AL, Didierlaurent AM. Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine. J Infect Dis. 2022 11 28; 226(11):1943-1948.
Score: 0.156
-
Johnson MJ, Liu C, Ghosh D, Lang N, Levin MJ, Weinberg A. Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence. J Infect Dis. 2022 04 19; 225(8):1477-1481.
Score: 0.149
-
Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Miao C, Canniff J, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, Parikh SA. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol. 2022 01 01; 97(1):90-98.
Score: 0.145
-
Schmid DS, Miao C, Leung J, Johnson M, Weinberg A, Levin MJ. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines. J Virol. 2021 05 24; 95(12).
Score: 0.140
-
Dagnew AF, Rausch D, Herv? C, Zahaf T, Levin MJ, Schuind A. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford). 2021 03 02; 60(3):1226-1233.
Score: 0.138
-
Schmader KE, Levin MJ, Chen M, Matthews S, Riley ME, Woo W, Herv? C, Grupping K, Schuind AE, Oostvogels L, Curran D. Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults. J Gerontol A Biol Sci Med Sci. 2021 02 25; 76(3):485-490.
Score: 0.138
-
Levin MJ. Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol Suppl. 2001; (17):151-60.
Score: 0.136
-
Duchon JM, Levin MJ, Gershon AA. Safety and Varicella Outcomes in In Utero-Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program. J Pediatric Infect Dis Soc. 2020 Sep 17; 9(4):449-453.
Score: 0.134
-
Colindres R, Wascotte V, Brecx A, Clarke C, Herv? C, Kim JH, Levin MJ, Oostvogels L, Zahaf T, Schuind A, Cunningham AL. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother. 2020 11 01; 16(11):2628-2633.
Score: 0.130
-
Harbecke R, Jensen NJ, Depledge DP, Johnson GR, Ashbaugh ME, Schmid DS, Breuer J, Levin MJ, Oxman MN. Recurrent herpes zoster in the Shingles Prevention Study: Are second episodes caused by the same varicella-zoster virus strain? Vaccine. 2020 01 10; 38(2):150-157.
Score: 0.126
-
Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P, Zahaf T, Dagnew AF, Chlibek R, Diez-Domingo J, Gorfinkel IS, Herv? C, Hwang SJ, Ikematsu H, Kalema G, Lal H, McNeil SA, Mrkvan T, Pauksens K, Smetana J, Watanabe D, Weckx LY, Cunningham AL. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vaccin Immunother. 2019; 15(12):2865-2872.
Score: 0.123
-
Hawkins KL, Gordon KS, Levin MJ, Weinberg A, Battaglia C, Rodriguez-Barradas MC, Brown ST, Rimland D, Justice A, Tate J, Erlandson KM. Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr. 2018 12 01; 79(4):527-533.
Score: 0.118
-
Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, Stinson D, Zerbe GO, Hayward AR. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis. 1998 Nov; 178 Suppl 1:S109-12.
Score: 0.117
-
Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, Esen M, Ikematsu H, Choma MK, Pauksens K, Ravault S, Salaun B, Schwarz TF, Smetana J, Abeele CV, Van den Steen P, Vastiau I, Weckx LY, Levin MJ. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. J Infect Dis. 2018 05 05; 217(11):1750-1760.
Score: 0.113
-
Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018 03 14; 36(12):1537-1541.
Score: 0.112
-
Levin MJ, Buchwald UK, Gardner J, Martin J, Stek JE, Brown E, Popmihajlov Z. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine. 2018 01 02; 36(1):179-185.
Score: 0.108
-
Herman L, Levin MJ, Rehm S. Shedding Light on Shingles: The Power of Prevention. Am J Med. 2016 Oct; 129(10):1137.
Score: 0.102
-
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, D?ez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barber? J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016 Sep 15; 375(11):1019-32.
Score: 0.101
-
Levin MJ, Hayward AR. The varicella vaccine. Prevention of herpes zoster. Infect Dis Clin North Am. 1996 Sep; 10(3):657-75.
Score: 0.101
-
Levin MJ. Can herpes zoster be prevented? Eur J Clin Microbiol Infect Dis. 1996 Jan; 15(1):1-3.
Score: 0.096
-
Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, Su SC, Parrino J, Popmihajlov Z, Weinberg A. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults. J Infect Dis. 2016 Jan 01; 213(1):14-22.
Score: 0.095
-
Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barber? J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May 28; 372(22):2087-96.
Score: 0.092
-
Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, Putzki N. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015 Jan; 72(1):31-9.
Score: 0.090
-
Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman CA, Marques A, Toney J, Boardman K, Su SC, Li X, Chan IS, Parrino J, Annunziato P, Oxman MN. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015 Mar 15; 60(6):900-9.
Score: 0.089
-
Hayward AR, Buda K, Levin MJ. Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunol. 1994; 7(1):31-6.
Score: 0.084
-
Silliman CC, Tedder D, Ogle JW, Simon J, Kleinschmidt-DeMasters BK, Manco-Johnson M, Levin MJ. Unsuspected varicella-zoster virus encephalitis in a child with acquired immunodeficiency syndrome. J Pediatr. 1993 Sep; 123(3):418-22.
Score: 0.082
-
Somekh E, Levin MJ. Infection of human fetal dorsal root neurons with wild type varicella virus and the Oka strain varicella vaccine. J Med Virol. 1993 Jul; 40(3):241-3.
Score: 0.081
-
Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013 Aug 15; 208(4):559-63.
Score: 0.080
-
Irwin MR, Levin MJ, Laudenslager ML, Olmstead R, Lucko A, Lang N, Carrillo C, Stanley HA, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Zhang JH, Johnson G, Oxman MN. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis. 2013 Apr; 56(8):1085-93.
Score: 0.079
-
Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M. Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother. 2013 May; 9(5):1177-84.
Score: 0.079
-
Lee KS, Zhou W, Scott-McKean JJ, Emmerling KL, Cai GY, Krah DL, Costa AC, Freed CR, Levin MJ. Human sensory neurons derived from induced pluripotent stem cells support varicella-zoster virus infection. PLoS One. 2012; 7(12):e53010.
Score: 0.078
-
Somekh E, Tedder DG, Vafai A, Assouline JG, Straus SE, Wilcox CL, Levin MJ. Latency in vitro of varicella-zoster virus in cells derived from human fetal dorsal root ganglia. Pediatr Res. 1992 Dec; 32(6):699-703.
Score: 0.078
-
Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis. 1992 Aug; 166(2):253-9.
Score: 0.076
-
Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012 Nov 15; 55(10):1320-8.
Score: 0.076
-
Schmader KE, Levin MJ, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012 Apr; 54(7):922-8.
Score: 0.073
-
Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, Fournier SO, Mansi JA, Brisson M. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012 Mar 09; 30(12):2047-50.
Score: 0.073
-
Benbernou A, Drolet M, Levin MJ, Schmader KE, Oxman MN, Johnson R, Patrick D, Camden S, Mansi JA, Brisson M. Association between prodromal pain and the severity of acute herpes zoster and utilization of health care resources. Eur J Pain. 2011 Nov; 15(10):1100-6.
Score: 0.070
-
Irwin MR, Levin MJ, Carrillo C, Olmstead R, Lucko A, Lang N, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Johnson G, Oxman MN. Major depressive disorder and immunity to varicella-zoster virus in the elderly. Brain Behav Immun. 2011 May; 25(4):759-66.
Score: 0.069
-
Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, Patrick D, Camden S, Mansi JA. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain. 2010 Nov; 11(11):1211-21.
Score: 0.067
-
Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010 Nov 09; 182(16):1731-6.
Score: 0.067
-
Drolet M, Brisson M, Levin MJ, Schmader KE, Oxman MN, Johnson RW, Camden S, Mansi JA. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010 Oct; 26(8):656-66.
Score: 0.067
-
Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, Chan IS, Yeh SS, Levin MJ, Harbecke RM, Oxman MN. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010 Sep; 58(9):1634-41.
Score: 0.067
-
Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, Levin MJ, Schmader KE, Gelb LD, Keay S, Neuzil K, Greenberg RN, Griffin MR, Davis LE, Morrison VA, Annunziato PW. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010 May 04; 152(9):545-54.
Score: 0.065
-
Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010 May; 48 Suppl 1:S2-7.
Score: 0.065
-
Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, Stek JE, Schlienger K, Chan IS, Silber JL. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine. 2010 Jun 07; 28(25):4204-9.
Score: 0.065
-
Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin. 2010 Apr; 6(4):318-21.
Score: 0.065
-
Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Sch?del F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009 Oct 01; 200(7):1068-77.
Score: 0.063
-
Gershon AA, Levin MJ, Weinberg A, Song LY, LaRussa PS, Steinberg SP, Bartlett P. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J. 2009 Jul; 28(7):653-5.
Score: 0.061
-
Oxman MN, Levin MJ. Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis. 2008 Mar 01; 197 Suppl 2:S228-36.
Score: 0.056
-
Gershon AA, Arvin AM, Levin MJ, Seward JF, Schmid DS. Varicella vaccine in the United States: a decade of prevention and the way forward. J Infect Dis. 2008 Mar 01; 197 Suppl 2:S39-40.
Score: 0.056
-
Cunningham AL, Breuer J, Dwyer DE, Gronow DW, Helme RD, Litt JC, Levin MJ, Macintyre CR. The prevention and management of herpes zoster. Med J Aust. 2008 Feb 04; 188(3):171-6.
Score: 0.056
-
Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007 Jul-Aug; 23(6):490-6.
Score: 0.053
-
Loparev VN, Rubtcova E, Seward JF, Levin MJ, Schmid DS. DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis. 2007 Feb 15; 195(4):502-10.
Score: 0.052
-
Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, Nurmikko TJ, Oaklander AL, Oxman MN, Pavan-Langston D, Petersen KL, Rowbotham MC, Schmader KE, Stacey BR, Tyring SK, van Wijck AJ, Wallace MS, Wassilew SW, Whitley RJ. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 01; 44 Suppl 1:S1-26.
Score: 0.052
-
Levin MJ, Zaia JA, Hershey BJ, Davis LG, Robinson GV, Segreti AC. Topical acyclovir treatment of herpes zoster in immunocompromised patients. J Am Acad Dermatol. 1985 Oct; 13(4):590-6.
Score: 0.047
-
Wang JP, Kurt-Jones EA, Shin OS, Manchak MD, Levin MJ, Finberg RW. Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. J Virol. 2005 Oct; 79(20):12658-66.
Score: 0.047
-
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 02; 352(22):2271-84.
Score: 0.046
-
Ellison MC, Zerbe GO, Levin MJ. Responder cell frequency estimation and binomial three-level nonlinear mixed effects model in limiting dilution assays. J Biopharm Stat. 2005; 15(1):165-78.
Score: 0.045
-
Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004 Aug; 5(6):344-56.
Score: 0.044
-
Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL, Schlienger K, Chalikonda I, Vessey SJ, Caulfield MJ. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003 Nov 01; 188(9):1336-44.
Score: 0.041
-
Levin MJ, Cai GY, Manchak MD, Pizer LI. Varicella-zoster virus DNA in cells isolated from human trigeminal ganglia. J Virol. 2003 Jun; 77(12):6979-87.
Score: 0.040
-
Curran D, Kim JH, Matthews S, Dessart C, Levin MJ, Oostvogels L, Riley ME, Schmader KE, Cunningham AL, McNeil SA, Schuind AE, Andrew MK. Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals. J Am Geriatr Soc. 2021 03; 69(3):744-752.
Score: 0.034
-
Dworkin RH, Carrington D, Cunningham A, Kost RG, Levin MJ, McKendrick MW, Oxman MN, Rentier B, Schmader KE, Tappeiner G, Wassilew SW, Whitley RJ. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antiviral Res. 1997 Jan; 33(2):73-85.
Score: 0.026
-
Harbecke R, Oxman MN, Arnold BA, Ip C, Johnson GR, Levin MJ, Gelb LD, Schmader KE, Straus SE, Wang H, Wright PF, Pachucki CT, Gershon AA, Arbeit RD, Davis LE, Simberkoff MS, Weinberg A, Williams HM, Cheney C, Petrukhin L, Abraham KG, Shaw A, Manoff S, Antonello JM, Green T, Wang Y, Tan C, Keller PM. A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol. 2009 Jul; 81(7):1310-22.
Score: 0.015
-
Bowden RA, McGavren L, Hayward AR, Levin MJ. Use of bone marrow fibroblasts to prepare targets for an HLA restricted-cytotoxicity assay system. J Clin Microbiol. 1984 Oct; 20(4):696-700.
Score: 0.011
-
Levin MJ, Leventhal S, Masters HA. Factors influencing quantitative isolation of varicella-zoster virus. J Clin Microbiol. 1984 Jun; 19(6):880-3.
Score: 0.011
-
Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio MA, LeGore J. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis. 1983 Apr; 147(4):737-43.
Score: 0.010
-
Irwin M, Costlow C, Williams H, Artin KH, Chan CY, Stinson DL, Levin MJ, Hayward AR, Oxman MN. Cellular immunity to varicella-zoster virus in patients with major depression. J Infect Dis. 1998 Nov; 178 Suppl 1:S104-8.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|